(Q24235442)

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Reflections on therapeutic trials in primary biliary cirrhosis: a quality of life oriented counter-view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Methotrexate therapy for primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Methotrexate for induction of remission in refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Interaction revisited: the difference between two estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Methotrexate as a steroid sparing agent for asthma in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Colchicine for primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Ursodeoxycholic acid for primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Epidemiology and natural history of primary biliary cirrhosis in a US community

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

A comparison of methods to detect publication bias in meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Characterization of antimitochondrial antibodies in health adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Natural history of early primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

The epidemiology of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Methotrexate for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Methotrexate for treating juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Review article: methotrexate in gastroenterology--dangerous villain or simply misunderstood?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Expression of MHC products by normal and abnormal bile duct epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Methotrexate for primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

Ultrastructural immunocytochemical analysis of lymphocytes infiltrating bile duct epithelia in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Randomized trial of chlorambucil for primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Methotrexate therapy of primary biliary cirrhosis: promising but worrisome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Methotrexate for primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

D-penicillamine treatment improves survival in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Aberrant expression of HLA-DR antigens on bileduct epithelium in primary biliary cirrhosis: relevance to pathogenesis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

A prospective trial of D-penicillamine in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Trial of penicillamine in advanced primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Primary biliary cirrhosis--a first step in prolonging survival

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Prescribing habits in primary biliary cirrhosis: a national survey

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Primary biliary cirrhosis: clinical features and outcome, with special reference to asymptomatic disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Primary Biliary Cirrhosis Treated with Low-Dose Oral Pulse Methotrexate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021

Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004385.PUB3

7 January 2021